53
Participants
Start Date
January 31, 2016
Primary Completion Date
September 30, 2017
Study Completion Date
December 31, 2017
IGIV-C 10%
IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
IGSC 20%
IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
Penn State University, Hershey
Children's Hospital of Richmond at VCU, VCU Medical Center, Richmond
Duke University Medical Center, Durham
Emory Children's Center, Atlanta
University of Miami - Batchelor Children's Research Institute, Miami
Allergy Associates of The Palm Beaches, PA, North Palm Beach
University of South Florida, St. Petersburg
The South Bend Clinic, South Bend
Children's Hospital of Michigan - Wayne State University, Detroit
Midwest Immunology, Plymouth
Rush University Medical Center, Chicago
Washington University Medical Center, St Louis
Oklahoma Institute of Allergy and Asthma Clinical Research, Oklahoma City
Vital Prospects Clinical Research Institute, PC, Tulsa
AARA Research Center, Dallas
Baylor Texas Children's Hospital, Houston
University of Texas Health Science Center at San Antonio, San Antonio
National Jewish Health, Denver
UCLA Medical Center, Los Angeles
AIRE Medical of Los Angeles, Santa Monica
Ottawa Hospital, Division of Infectious Disease and Respirology, Ottawa
CHU Sainte-Justine, Montreal
McGill University Health Center, Montreal
Clinique d'asthme et d'allergie de Quebec, Québec
The Hospital for Sick Children, Toronto
Lead Sponsor
Grifols Therapeutics LLC
INDUSTRY